Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo aims to stop immune attack after kidney transplant

NCT ID NCT05049850

First seen Nov 01, 2025 · Last updated Jun 01, 2026 · Updated 25 times

Summary

This study tested whether a drug called imlifidase, given with other medications, could prevent the immune system from attacking a new kidney in highly sensitized patients. These patients have a very high risk of rejecting a donated kidney. The study was stopped early after only 3 participants, so the results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • NYU Langone Health Transplant Institute

    New York, New York, 10016, United States

Conditions

The condition(s) this trial relates to.

chronic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.